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Summary.-Intrapleurally injected cells of an ascitic rat tumour produced intra-
pleural effusions and solid pleural deposits. BCG, or its methanol extraction
residue (MER) injected into the pleural space, suppressed tumour development and
prolonged survival. Treatment was effective if given a few days before or after
tumour injection. In contrast, active specific immunotherapy by repeated s.c.
injection of viable or radiation-attenuated tumour cells in admixture with BCG was
unsuccessful, and did not improve the response to intrapleural BCG treatment.
MANY experimental studies have in-
dicated the feasibility of using immuno-
therapeutic techniques in the clinical
treatment of malignant disease. While
systemic administration ofadjuvants such
as Bacillus Calmette-Guerin (BCG) may
be tumour suppressive in some experi-
mental circumstances, introduction of
adjuvant materials directly into the en-
vironment of a tumour is frequently the
most efficient means of therapy. For
example, injection of transplanted cells of
rat, mouse, hamster and guinea-pig tum-
ours with BCG often suppresses their
growth, and intralesional injections may
also retard progressive development or
cause regressions (reviewed by Laucius
et al., 1974; Bast et al., 1974). As an
alternative to adjuvant contact therapy,
specific active immunotherapy employing
vaccines of tumour cells in admixture
with adjuvant has also been shown to
control growth of distant tumour deposits
(Baldwin and Pimm, 1973a, b; Bartlett
and Zbar, 1972) although the indication is
that this form of treatment may not be as
efficient as contact therapy (Baldwin and
Pimm, 1973a).
The objective of the studies to be
described here was to extend previous
experiments on the BCG treatment of
pleural tumour growths (Pimm and Bald-
win, 1975a). These tests have been
carried out with the transplanted rat
hepatoma D23 in an ascitic form, which
will grow in a pleural effusion when
injected into the thorax. Experiments
have been carried out to compare the
relative efficiency ofintrapleurally injected
BCG and specific active immunotherapy;
to assess the possible synergistic effects
between these forms of treatment; and to
examine the feasibility of using a sub-
cellular fraction of BCG, the methanol
extraction residue, (MER) originally de-
scribed by Weiss and Wells (1960) in place
ofintact organisms.
MATERIALS AND METHODS
Tumour. Hepatoma D23, originally in-
duced by 4-dimethylaminoazobenzene in an
adult male rat of the Department's inbred
Wistar strain, was used in the present studies,
in its ascitic form, maintained by weekly i.p.
passage of 107 tumour cells (Robins, 1975).
This tumour is moderately immunogenic, so
immunization with irradiated (15,000 R)
tumour cells protects rats against challenge
with up to 5 x 105 cells given intrapleurally,
i.p. or s.c., although growth will occur from
inocula aslow as 104 cellsinuntreatedanimals.
Bacillus Calmette Gue'rin (BCG).-Freeze-
dried BCG vaccine (percutaneous) was sup-
plied by Glaxo Research Ltd., Greenford,BCG TREATMENT OF PLEURAL EFFUSIONS
Middlesex. The vaccine was reconstituted
in water to 10 mg moist weight of organisms/
ml.
Methanol Extraction Residue (MER).
The methanol-insoluble fraction of phenol-
killed, acetone-washed Phipps strain BCG
(NSC 143769 Lot 675738-00607) was supplied
as a desiccated powder by the Divisioni of
Cancer Treatment, National Cancer Institute,
Bethesda, Maryland. It was reconstituted
with physiological saline by grinding in a
Potter-Elvehjem homogenizer and sterilized
by heating to 70°C for 15 min before use
(Hopper, Pimm and Baldwin, 1975).
Experimental protocol.-Pleural growth of
tumour was produced by injection of ascitic
cell aspirates (1 x 105 to 2 x 105 cells) into
the pleural cavity through the thoracic wall
in the region of the right axilla using a 25 G
needle. Growth took the form of a single
cell suspension in a pleural effusion, often
accompanied by solid masses oni the parietal
and visceral pleura. Treatment was given
by either: (a) intrapleural injection of BCG
or MER; (b) repeated s.c. injections of
2 x 106 60Co-y-irradiated (15,000 R) tumiour
cells, alone or mixed with 500 jtg moist wieight
of BCG; (c) repeated s.c. injections of 1(5
viable tumour cells mixed with BCG; (d)
intrapleural injection of BCG and repeated
s.c. injections of irradiated cells and BCG.
Assessment of growrth. Rats were killed
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when showing respiratory distress cause(d by
pleural tumour growth. Survivals were ex-
pressed in days from initial tumour cell
injection.
RESULTS
Fig. I illustrates the result of the
treatment of pleural growth from an
initial inoculum of 2 x 105 tumour cells.
All (5/5) control animals had to be killed
after 12 days, because of respiratory
distress caused by intrapleural tumour
development. The survivals of animals
treated by repeated s.c. injections of
2 x 106 irradiated tumour cells, either
alone or mixed with BCG (500,g moist
weight of organisms) was comparable to
that of controls (survivals 12-19 days and
12-20 days). In contrast, intrapleural
injections of BCCGr alone, prolonged the
survival of4/5 rats to between 20-32 days,
and one rat survived tumour-free to 70
days, at which time the experiment was
terminated. Treatment by combined
intrapleural injection and specific immuno-
therapy with irradiated cells and BCG,
similarly prolonged survival, and here 3/5
animals remained tumour-free to 70 days.
In the second test (Fig. 2) treatment by
repeated injections of irradiated cells
TIME (DAYS)
FiG. 1.-Survival of rats challenged intrapleurally with D23 ascites cells (2 x 105 cells) anid treated with: * *, 500 ,ug BCG intrapleurally, Day 0: 0 .* 2 x 106 irradiated D23 ascites cells
s.c. Days 0, 7, 9: A A, 2 x 106 irra(iated D23 ascites cells + 500 ,ig BCG s.c. Days 0, 7, 9:
H - , 500 ,ig BCG intrapleurally, Day 0, 2 x 106 irradiate(l D23 ascites cells -+ 500 ,ug BCG s.x. Days 0, 7, 9: 0 O, control, no treatment.
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FIa. 2. Survival of rats challenged intrapleurally with D23 ascites cells (2 x 105 cells) and treated
with: r- Lr, 500 Mtg BCG intrapleurally, Day 0: A A, 2 x 106 irradiated D23 ascites cells s.c.
Days 0, 5, 10: * *, 2 x 106 irradiated D23 ascites cells + 500,g BCG s.c. Days 0, 5, 10:
* *, 500 Mtg BCG intrapleurally Day 0, 2 x 106 irradiated D23 ascites cells + 500,g BCG
s.c. Days 0, 5, 10: 0 O, control, no treatment.
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Fia. 3. Survival of rats challenged intrapleurally with D23 ascites cells (105 cells) and treated with:
* *, 500 Mg BCG intrapleurally, Day 0: 0 QO, 105 viable D23 ascites cells + 500 Mug BCG
s.c. Days 0, 4: * 0, control, no treatment.
with or without BCG again produced no
beneficial effect, while a single intra-
pleural BCG injection prolonged survival
to 24-60 days, compared with 13-15 days
in controls, and 2/8 treated animals
remained tumour-free. In this experi-
ment, specific active immunotherapy in
addition to intrapleurally injected BCG
did not augment its effect, and again only
2/8 animals remained tumour-free.
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Fi(r. 4. Treatment of intrapleural D23 ascites cells (105 cells) by intrapleural injection of BCG
(500 ,ig): A A 4 days before challenge: * *, 2 days before challenge: O IF1, day of
challenge: 0 *, 2 days after challenge: O~ 0, control, no treatment.
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FIG. 5. Treatment, of intrapleural D23 ascites cells (105 cells) by intrapleural injection of MER of BCG
(100 t&g): * 0, (lay of challenge: *, one day after challenge: O 0, control, no treatment.
Previous tests on the specific active
immunotherapy of s.c. tumour deposits
have suggested that irradiated tumour
cells mixed with BCG may not be as
effective as a vaccine incorporating viable
cells (Baldwin and Pimm, 1973a). Con-
sequently, a further test was carried out
in which rats receiving intrapleurally
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injected tumour cells were treated by
repeated s.c. injection of 105 viable cells
mixed with BCG (Fig. 3). No growth
occurred in the s.c. sites, due to the
presence of BCG, but this treatment
exerted no influence on the pleural
growth oftumour. Again however, intra-
pleurally injected BCG markedly pro-
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longed survival, a proportion of animals
remaining tumour-free.
The tests illustrated in Fig. 4 were
carried out to assess the effect of BCG
administered before or after tumour cell
injection. BCG given 4 days before to 2
days after intrapleural tumour challenge,
markedly prolonged survival, comparable
to the effect achieved with BCG given at
the same time as tumour.
A final test was carried out to examine
the possibility of using methanol extrac-
tion residue (MER) of BCG in place of the
intact organisms. In this case (Fig. 5)
control animals all had to be killed at 14
days, but intrapleural injection of MER
(200,ig dry wt.) at the same time as
tumour cells, prolonged survival to 18-28
days. Furthermore MER injected
1 day after tumour challenge prolonged
survivals up to 45 days.
DISCUSSION
These studies confirm and extend the
previous findings on BCG treatment of
pleural growth of transplanted solid rat
sarcomata and the hepatoma D23 (Pimm
and Baldwin, 1975a). The present
studies emphasize the superior therapeutic
effect of BCG injected directly into the
region of tumour development, even if
treatment is given before or after tumour
challenge. Most importantly, intrapleu-
rally injected BCG markedly prolongs
survival of rats receiving intrapleural
tumour cell injections, but repeated treat-
ment by active immunotherapy using
viable or radiation-killed tumour cells
mixed with BCG was relatively ineffective
and, moreover, did not augment the effect
ofintrapleurally injected organisms. The
MER of Weiss and Wells (1960) was also
effective in the pleural cavity, extending
the previous report on its tumour-
suppressive action when injected s.c.
mixed with tumour cells (Hopper, Pimm
and Baldwin, 1975).
Although the mechanism of tumour
suppression by this type of adjuvant
contact therapy is as yet unresolved, there
is considerable evidence that the effect is
more dependent upon local activation of
non-specific host factors, probably macro-
phages, than upon general immunostimu-
lation. For example, BCG contact sup-
pression of s.c. rat tumour growth is not
abrogated by immunosuppression by
thymectomy and/orwholebodyirradiation
(Moore, Lawrence and Nisbet, 1975;
Pimm and Baldwin, 1976) and is also
effective against rat tumours transplanted
to athymic "nude " mice (Pimm and
Baldwin, 1975b). In contrast, BCG con-
tact suppression in both rats (Chassoux
and Salomon, 1975; Hopper, Pimm and
Baldwin, 1976) and athymic mice
(Hopper et al., 1976) is abrogated by
silica-induced host macrophage depletion
(Pimm and Baldwin, 1976). The impli-
cation from this is thatclinicalextensionof
this type oftumour treatment may still be
feasible in patients immunosuppressed by
radiotherapy or chemotherapy, as long as
macrophage function is not impaired, and
clinically, intrapleurally injected BCG is
currently being tested for effectiveness in
controlling malignant pleural effusions in
advanced mesothelioma patients (Elmes,
personal communication). The present
and previous report (Pimm and Baldwin,
1975a) with experimental tumours suggest
that intrapleural administration of BCG-
will probably be the most effective route
for treatment of malignant pleural
effusions; that this treatment is superior
to active immunotherapy with distant
injections of tumour cells mixed with
BCG; and that the effect of simple intra-
pleurally administered BCG might not be
enhanced by additional BCG treatment
elsewhere.
For the clinical management of lung
cancer, also, McKneally, Maver and Kausel
(1976) have demonstrated that a single
post-operative injection of BCG into the
pleural space improves survival after
surgery for Stage I disease. It is not
clear, however, whether this effect really
depends upon regional application of the
vaccine, since beneficial effects have also
been observed in lung cancer following
administration of BCG at distant intra-
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dermal sites (Pines, 1976; Edwards and
Whitwell, 1974). However, Yamamoto
et al. (1975) have shown, in the guinea-pig,
that a delayed hypersensitivity reaction
in the pleural cavity, in response to intra-
pleurally injected PPD, does produce
histological changes in lung tissue as well
as in the pleural space. This response in
pulmonary tissue was an infiltration of
leucocytes, predominantly mononuclear
cells, and reached a peak 18-24 h after
intrapleural PPD injection, at which time
the response in the pleural space was also
at its peak. Clearly the feasibility of
suppressing growth oftumour in the lungs,
as well as the pleural cavity, by reaction
to intrapleurally injected mycobacterial
preparations requires experimental
investigation.
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